Why the study?
Do NOBORI biolimus-eluting stents improve clinical outcomes compared to XIENCE/PROMUS everolimus-eluting stents in patients with small vessel disease?
Do NOBORI biolimus-eluting stents improve clinical outcomes compared to XIENCE/PROMUS everolimus-eluting stents in patients with small vessel disease?
Biolimus-eluting stents show similar two-year clinical outcomes to everolimus-eluting stents in small coronary artery disease, supporting their use in this population.
Answers are grounded in this paper and cite their sources.
May support BES as alternative in small vessel disease; observational data leaves randomized confirmation open.
Two-year clinical outcomes of BES are similar to those of CoCr-EES in patients with small vessel disease. The use of BES is acceptable for small coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Jinnouchi et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: